DRAWINGS





Figure 1: Structure and formulation of the pharmaceutical compositions






Figure 2: Comparative appearance of minigranules without anti-agglomerant (top) and with an excess of anti-agglomerant (bottom)





Figure 3: In vitro dissolution profiles



5

Figure 4: Modelled *in vitro* dissolution profiles
= profiles of fractions absorbed *in vivo*




Figure 5: Predicted plasma concentrations obtained by convolution




Neutral core
Trimetazidine dihydrochloride
HPMC
Inner phase
Outer layer:
Ethylcellulose
Talc
Acetyl tributyl citrate

Figure 1






Figure 2



100
90
80
70
60
50
40
30
20
10
0
% release
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (hrs.)
E110118
E110120
E110121
E110124
P110055

Figure 3



100
90
80
70
60
50
40
30
20
10
0
% release
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (hrs.)
E110118
E110120
E110121
E110124
E110155

Figure 4



Concentration (ng/mL)
Time (hrs.)
E110118
E110120
E110121
E110124
E110155

Figure 5